Chuling Fang

457 total citations
18 papers, 354 citations indexed

About

Chuling Fang is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Oncology. According to data from OpenAlex, Chuling Fang has authored 18 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 6 papers in Physiology and 4 papers in Oncology. Recurrent topics in Chuling Fang's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers), Sarcoidosis and Beryllium Toxicity Research (6 papers) and CAR-T cell therapy research (3 papers). Chuling Fang is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers), Sarcoidosis and Beryllium Toxicity Research (6 papers) and CAR-T cell therapy research (3 papers). Chuling Fang collaborates with scholars based in China, United States and United Kingdom. Chuling Fang's co-authors include Zuojun Xu, Terrence M. Donohue, Danièle Lucas, Magnus Ingelman‐Sundberg, Samuel W. French, Paul Fu, J. Li, B.A. French, Hui Huang and Xiaoyan Jing and has published in prestigious journals such as PLoS ONE, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Chuling Fang

16 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chuling Fang China	10	139	136	113	99	76	18	354
Marcelle de Carvalho Ribeiro United States	9	73 0.5×	265 1.9×	23 0.2×	35 0.4×	200 2.6×	11	500
Koichiro Ohashi Japan	7	81 0.6×	150 1.1×	39 0.3×	16 0.2×	142 1.9×	23	394
Nobuhito Taniki Japan	14	52 0.4×	286 2.1×	25 0.2×	50 0.5×	131 1.7×	43	589
Alexandra Griffiths United States	9	54 0.4×	118 0.9×	20 0.2×	52 0.5×	110 1.4×	15	296
Christina K. Cajigas‐Du Ross United States	7	97 0.7×	106 0.8×	54 0.5×	14 0.1×	106 1.4×	8	276
Kazunobu Monden Japan	13	66 0.5×	126 0.9×	38 0.3×	30 0.3×	68 0.9×	26	479
Michael Pimienta United States	7	104 0.7×	254 1.9×	21 0.2×	28 0.3×	200 2.6×	12	491
S W French United States	10	236 1.7×	254 1.9×	30 0.3×	29 0.3×	91 1.2×	16	488
Hisao Ezaki Japan	10	35 0.3×	267 2.0×	25 0.2×	61 0.6×	132 1.7×	12	439
Zun Xiang China	13	69 0.5×	216 1.6×	23 0.2×	39 0.4×	259 3.4×	17	581

Countries citing papers authored by Chuling Fang

Since Specialization

Citations

This map shows the geographic impact of Chuling Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chuling Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chuling Fang more than expected).

Fields of papers citing papers by Chuling Fang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chuling Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chuling Fang. The network helps show where Chuling Fang may publish in the future.

Co-authorship network of co-authors of Chuling Fang

This figure shows the co-authorship network connecting the top 25 collaborators of Chuling Fang. A scholar is included among the top collaborators of Chuling Fang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chuling Fang. Chuling Fang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Fang, Chuling, Lixin Wang, Weiqiang Zhao, et al.. (2025). Integrated clinical and single-cell profiling of BCMA CAR-T therapy in relapsed/refractory multiple myeloma. Journal of Translational Medicine. 23(1). 1251–1251.

Wang, Lixin, Chuling Fang, Weiqiang Zhao, et al.. (2024). Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial. Blood Cancer Journal. 14(1). 130–130. 14 indexed citations

Fang, Chuling, et al.. (2023). Concurrent chronic myelomonocytic leukemia and gastric carcinoma: a case report and literature review. AME Case Reports. 7. 37–37. 2 indexed citations

Wang, Lixin, Chuling Fang, Weiqiang Zhao, et al.. (2023). Favorable response of a patient with primary B/myeloid mixed phenotype acute Leukemia to CD19-CAR-T: Case report and literature review. Medicine. 102(50). e36397–e36397.

Zhang, Qian, Meijun Zhang, Chuling Fang, et al.. (2022). Exome Sequencing Reveals Genetic Variability and Identifies Chronic Prognostic Loci in Chinese Sarcoidosis Patients. Frontiers in Oncology. 12. 910227–910227. 2 indexed citations

Liu, Tianju, et al.. (2022). B7H3-dependent myeloid-derived suppressor cell recruitment and activation in pulmonary fibrosis. Frontiers in Immunology. 13. 901349–901349. 15 indexed citations

Fang, Chuling, Hui Huang, Yujia Feng, et al.. (2021). Whole-exome sequencing identifies susceptibility genes and pathways for idiopathic pulmonary fibrosis in the Chinese population. Scientific Reports. 11(1). 1443–1443. 4 indexed citations

Jing, Xiaoyan, Wei Sun, Xiaoyu Yang, et al.. (2021). CCAAT/enhancer-binding protein (C/EBP) homologous protein promotes alveolar epithelial cell senescence via the nuclear factor-kappa B pathway in pulmonary fibrosis. The International Journal of Biochemistry & Cell Biology. 143. 106142–106142. 13 indexed citations

Fang, Chuling, et al.. (2021). B7H3 expression and significance in idiopathic pulmonary fibrosis. The Journal of Pathology. 256(3). 310–320. 9 indexed citations

10.

Fang, Chuling, Hui Huang, Qian Zhang, et al.. (2020). Relation between sex hormones and leucocyte telomere length in men with idiopathic pulmonary fibrosis. Respirology. 25(12). 1265–1273. 17 indexed citations

11.

Fang, Chuling, Hui Huang, Jian Guo, Martin Ferianc, & Zuojun Xu. (2020). Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice. PLoS ONE. 15(1). e0228390–e0228390. 19 indexed citations

12.

Zhang, Qian, Hui Huang, Chuling Fang, et al.. (2020). [Whole exome sequencing and analysis of a Chinese family with familial pulmonary sarcoidosis].. PubMed. 43(6). 525–531. 2 indexed citations

13.

Li, Shan, Yongzhe Liu, Hui Huang, et al.. (2019). [The role of histone deacetylases in the pathogenesis of idiopathic pulmonary fibrosis and cryptogenic organizing pneumonia].. PubMed. 42(5). 361–366. 1 indexed citations

14.

Fang, Chuling, Qian Zhang, Na Wang, Xiaoyan Jing, & Zuojun Xu. (2019). Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study.. PubMed. 36(3). 217–227. 26 indexed citations

15.

Zhao, Yang, et al.. (2018). [The role of B cell activating factor in the differential diagnosis of usual interstitial pneumonia].. PubMed. 41(7). 544–550. 6 indexed citations

16.

Fang, Chuling, Hui Huang, & Zuojun Xu. (2016). Immunological Evidence for the Role of Mycobacteria in Sarcoidosis: A Meta-Analysis. PLoS ONE. 11(8). e0154716–e0154716. 46 indexed citations

17.

Lucas, Danièle, J. Li, B.A. French, et al.. (2000). Inhibition of Ethanol-Induced Liver Disease in the Intragastric Feeding Rat Model by Chlormethiazole. Proceedings of The Society for Experimental Biology and Medicine. 224(4). 302–308. 148 indexed citations

18.

Lucas, Danièle, J. Li, B.A. French, et al.. (2000). Inhibition of Ethanol‐Induced Liver Disease in the Intragastric Feeding Rat Model by Chlormethiazole. Proceedings of The Society for Experimental Biology and Medicine. 224(4). 302–308. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact